All studies
AuthorisedHuman Pharmacology (Phase I)- First administration to humansInterventional

A Randomized, Double-Masked, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ETHY-001.

This clinical trial is looking at a new experimental medicine called ETHY-001. It is designed to treat thyroid eye disease, a condition where the tissues around the eyes become swollen and inflamed. Because this is a Phase 1 trial, it is the first time the medicine is being tested in humans. The main goal is not yet to cure the condition, but to find out if the treatment is safe, what side effects it might cause, and how the body breaks it down. Volunteers will be split by chance into two groups. One group will receive a single dose of ETHY-001, while the other will receive a dummy treatment (saline). Neither the volunteers nor the study doctors will know who gets which treatment until the trial ends. Doctors will monitor everyone closely with regular health checks and blood tests.

At a glance

Status
Authorised
Phase
Human Pharmacology (Phase I)- First administration to humans
Sponsor
Ethyreal Bio Inc.
Enrolment target
7
Start
21 Oct 2026

What is this study about?

Thyroid eye disease is an autoimmune condition where the body's immune system attacks the muscles and fatty tissues around the eyes. This can cause redness, swelling, bulging eyes, and double vision. While there are some treatments available, researchers are constantly working to find newer, better options that carry fewer unwanted side effects.

This study looks at a new drug called ETHY-001. It is an early-stage study, known as a Phase 1 trial, which means this is the first time the medicine is being given to people. The primary goal is to find out if the drug is safe, how well the human body tolerates it, and how it moves through the bloodstream over time.

To ensure fair results, the trial uses a dummy treatment (a simple salt water solution called a placebo) alongside the real drug. Patients are placed into groups by chance, and doses start very low with a few people before slowly increasing for newer groups if it proves safe. This careful approach helps doctors identify the safest possible dose for future studies.

Key takeaways

  • Tests a new experimental medicine (ETHY-001) for thyroid eye disease.
  • This is a Phase 1 trial focusing primarily on safety and side effects.
  • Participants will receive either a single dose of the drug or a dummy salt water injection.
  • Open to adults aged 18 and older.
  • Involves clinic visits, blood tests, and close health monitoring.

Who may be eligible?

This study is open to adults aged 18 and older who are living with thyroid eye disease. Both men and women can take part.

Because this is an early safety trial, volunteers will need to meet specific health checks to ensure taking part is safe for them. The study team will look closely at your overall medical history, current medications, and thyroid blood test results before deciding if you can join.

People who are pregnant, breastfeeding, or managing certain other serious long-term medical conditions may not be able to participate. Your trial doctor will go through the full list of rules with you in detail.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am at least 18 years old.
  2. I have been diagnosed with thyroid eye disease.
  3. I am willing to attend clinic visits for health checks and blood tests.
  4. I am comfortable receiving either the real medicine or a dummy treatment.
  5. I am not currently pregnant or breastfeeding.
Answer every question to see your result.

What does participation involve?

Taking part involves attending an initial screening visit to check if the trial is right for you. If you join, you will receive a single dose of either ETHY-001 or the saline dummy treatment. You will need to stay at the clinic for monitoring immediately after receiving your dose so doctors can watch for any reactions. Over the following weeks, you will return for scheduled follow-up visits. During these visits, the team will check your blood, test your thyroid function, monitor your eyes, and ask about any symptoms or side effects you might have noticed. The trial team will confirm the exact number of visits and the full study duration before you agree to join.

Potential risks and benefits

Because this is the first time ETHY-001 has been given to humans, there is no guarantee that taking part will improve your eye symptoms, and you might receive a dummy treatment instead. You may also experience unexpected side effects. However, the trial team will watch your health very closely throughout. The information gathered will help doctors develop better treatments for people with thyroid eye disease in the future. Taking part is entirely voluntary, and you can change your mind and leave the study at any time without giving a reason and without affecting your normal NHS care.

Locations (2)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Germany
  • —
    Unverified
    Spain

Common questions

What does a Phase 1 trial mean?

A Phase 1 trial is the earliest stage of human testing. It focuses mainly on safety, checking for side effects and seeing how the body processes the new medicine.

What is a placebo?

A placebo is a harmless dummy treatment that looks just like the real medicine but contains no active drug. In this trial, a simple salt water solution is used.

Will I definitely receive the new medicine?

No. A computer randomly decides whether you receive ETHY-001 or the placebo. Neither you nor your doctor can choose which one you receive.

Do I have to pay to take part?

No, clinical trials do not charge you for the study medication or tests. Many trials also help cover travel expenses for clinic visits.

Can I leave the study if I change my mind?

Yes, you can leave the study at any time. Your decision will not affect your relationship with your doctors or your regular NHS care.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.